Using a novel systems-epigenomics algorithm (SEPIRA) for inferring TF binding activity from either gene expression or DNAm data, we have shown that lung-specific TFs become consistently and preferentially inactivated in lung cancer, in precursor lung cancer lesions, and in some instances also in dysplasias and normal cells exposed to smoke carcinogens. The gene discussed is TF; the disease is lung cancer.